Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#102 / 102 Total
RPTX - Repare Therapeutics Inc - Stock Price Chart
TickerRPTX [NASD]
CompanyRepare Therapeutics Inc
CountryCanada
IndustryBiotechnology
Market Cap152.82MEPS (ttm)-1.10
P/E-EPS this Y-6.53%
Forward P/E-EPS next Y-30.95%
PEG-EPS past 5Y-41.74%
P/S1.56EPS next 5Y-
P/B0.66EPS Q/Q135.98%
Dividend-Sales Q/Q822.93%
Insider Own32.40%Inst Own54.84%
Insider Trans9.61%Inst Trans-4.79%
Short Float2.12%EarningsMay 07/a
Analyst Recom1.43Target Price15.33
Avg Volume198.27K52W Range2.98 - 13.85
May-08-24 07:39AM Top Premarket Gainers (MT Newswires) +15.55%
07:31AM Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
May-07-24 10:55PM RPTX Stock Earnings: Repare Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:05PM Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results (Business Wire)
Apr-30-24 07:05AM Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition (Business Wire)
07:05AM Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition (Business Wire)
Apr-26-24 04:05PM Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors (Business Wire)
Feb-29-24 07:05AM Repare Therapeutics to Participate in Two Upcoming Investor Conferences (Business Wire) +5.30%
Feb-28-24 07:36AM Repare Therapeutics Inc (RPTX) Reports Financial Outcomes for Q4 and Full Year 2023 (GuruFocus.com)
07:05AM Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company was founded on September 6, 2016 and is headquartered in Saint-Laurent, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Segal Lloyd MitchellPRESIDENT AND CEOApr 01 '24Sale4.632,49111,533107,558Apr 01 09:31 PM
Forte SteveEVP, CHIEF FINANCIAL OFFICERApr 01 '24Sale4.617893,63744,775Apr 01 09:30 PM
Zinda MichaelEVP, CHIEF SCIENTIFIC OFFICERApr 01 '24Sale4.664101,91171,908Apr 01 09:28 PM
Koehler MariaEVP, CHIEF MEDICAL OFFICERApr 01 '24Sale4.663001,398231,409Apr 01 09:27 PM
Segal Lloyd MitchellPRESIDENT AND CEOMar 28 '24Sale4.622,65012,243110,049Apr 01 09:31 PM
1⋯67891011
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.